SEC Form 4	
------------	--

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287					
Estimated average burden						
hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. <i>See</i> Instruction 1(b).

FORM 4

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	nd Address of tula Pad	Reporting Person*			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Arcturus Therapeutics Holdings Inc.</u> [ ARCT ]						Rela Check	on(s) to Issu 10% Ow	ner					
(Last)	(F	First)	(Middle)	_ '									Х	Officer ( below)	give title		Other (s below)	pecify
l` í	`	HERAPEUTICS	( )		3. Date of Earliest Transaction (Month/Day/Year) 06/21/2022								Chief S	Scientific	: Offi	cer & CO(		
10628 SCIENCE CENTER DRIVE, SUITE 250				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable						
(Street) SAN DII		A	92121 (Zip)	_									ne) X			•	rting Person One Report	I
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) Date (Month/I			ansactio	ction 2A. Deemed 3. 4. Securities Ac Execution Date, Transaction Disposed Of (D			es Acquir	ed (A) or		5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
								Code	v	Amount	(A) o (D)	r Price	Price Reported (I (Instr. 3 and 4)			Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code 8)		5. Number Derivative Securities Acquired or Dispos of (D) (Ins 4 and 5)	e (A) ed	Expiration Date of 5 (Month/Day/Year) Un De			of Secur Underlyi	ng re Securit	Derivati Security urity (Instr. 5)		/e derivativ	ve es ally ng d	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Amour or Numbe of Shares	er		(Instr. 4)	011(5)		

1. Represents options to purchase shares of common stock conditionally approved by the Board of Directors on December 10, 2021, subject to approval of an amendment to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan by the Company's stockholders, which approval was obtained at the Company's 2022 Annual Meeting of Stockholders held on June 21, 2022.

\$34.57

**Explanation of Responses:** 

Employee Stock Option

(right to buy)

2. The shares underlying this option vest 25% on December 10, 2022, the first anniversary of the date this award was conditionally approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

(2)

<u>/s/ Ilan Katz, attorney-in-fact</u>	<u>06/23/2022</u>
** Signature of Reporting Person	Date

85,000

\$0.00

85,000

D

Common Stock

12/10/2031

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

06/21/2022

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

A

85,000<sup>(1)</sup>

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.